Female infertility drug market to exhibit CAGR of 3.4 percent
Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
List view / Grid view
Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
California’s state governor has signed a bill which will stop drug makers from paying generic drug producers to stay off the market.
Despite plans to lower drug prices in the US, political divisions have muddied the waters. This article examines the efforts made by those involved and the possibilities of their success.
The global pharma contract development and manufacturing organisation (CDMO) outsourcing market is predicted to grow.
The UK Competition and Markets Authority has alleged that Aspen paid two other pharmaceutical companies to ensure they were the only supplier of a drug to the NHS.
The government has announced new measures to prevent parallel exporting to ease the supply chain, in an effort to reduce medicine shortages.
A survey of pharmacists has discovered that UK pharmacies experienced shortages across all 36 medicine categories in the last six months.
The UK National Audit Office has released a report which has found that medicine supply to the UK will be delayed in the event of a no-deal Brexit.
Research has found that the pharmaceutical industry in India must encourage innovation in order to keep up with the growth of the sector.
This article explores the potential of readily available technology to address current traceability challenges as well as more wide-ranging issues in the pharmaceutical industry.
NICE has announced that it will not be recommending erenumab, an injectable migraine treatment, due to issues with cost and its long-term effectiveness.
Increasing demand for convenient drug delivery, as well as an increase in diseases such as diabetes, has fuelled the global injectable drug delivery market.
King Pharmaceuticals Limited and Alissa Healthcare Research Limited have admitted to sharing information to keep drug prices up.